Morbidity, Mortality, and Pathologic Outcomes of Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer Short-term Outcomes From a Multicenter Randomized Controlled Trial
Author:
Open Access
- 11 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 277 (1) , 1-6
Abstract
Objective: To determine the morbidity, mortality, and pathologic outcomes of transanal total mesorectal resection (taTME) versus laparoscopic total mesorectal excision (laTME) among patients with rectal cancer with clinical stage I to III rectal cancer below the peritoneal reflection. Background: Studies with sufficient numbers of patients allowing clinical acceptance of taTME for rectal cancer are lacking. Thus, we launched a randomized clinical trial to compare the safety and efficacy of taTME versus laTME. Methods: A randomized, open-label, phase 3, noninferiority trial was performed at 16 different hospitals in 10 Chinese provinces. The primary endpoints were 3-year disease-free survival and 5-year overall survival. The morbidity and mortality within 30 days after surgery, and pathologic outcomes were compared based on a modified intentiontotreat principle; this analysis was preplanned. Results: Between April 13, 2016, and June 1, 2021, 1115 patients were randomized 1:1 to receive taTME or laTME. After exclusion of 26 cases, modified intentiontotreat set of taTME versus laTME groups included 544 versus 545 patients. There were no significant differences between taTME and laTME groups in intraoperative complications [26 (4.8%) vs 33 (6.1%); difference, −1.3%; 95% confidence interval (CI), −4.2% to 1.7%; P=0.42], postoperative morbidity [73 (13.4%) vs 66 (12.1%); difference, 1.2%; 95% CI, −2.8% to 5.2%; P=0.53), or mortality [1 (0.2%) vs 1 (0.2%)]. Successful resection occurred in 538 (98.9%) versus 538 (98.7%) patients in taTME versus laTME groups (difference, 0.2%; 95% CI, −1.9% to 2.2%; P>0.99). Conclusions: Experienced surgeons can safely perform taTME in selected patients with rectal cancer.Keywords
This publication has 22 references indexed in Scilit:
- Incidence and Risk Factors for Anastomotic Failure in 1594 Patients Treated by Transanal Total Mesorectal ExcisionAnnals of Surgery, 2019
- Short- and long-term outcomes of transanal versus laparoscopic total mesorectal excision for mid-to-low rectal cancer: a meta-analysisSurgical Endoscopy, 2018
- A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and designBMC Cancer, 2017
- COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancerSurgical Endoscopy, 2015
- Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic OutcomesJAMA, 2015
- Transanal Total Mesorectal Excision in Rectal CancerAnnals of Surgery, 2015
- Transanal Endoscopic ProctectomyDiseases of the Colon & Rectum, 2013
- NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistanceSurgical Endoscopy, 2010
- Appropriate body-mass index for Asian populations and its implications for policy and intervention strategiesThe Lancet, 2004
- The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?British Journal of Surgery, 1982